Enjoy complimentary customisation on priority with our Enterprise License!
The urinary tract infection (UTI) treatment market share is expected to increase by USD 2.66 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.71%.
This urinary tract infection (UTI) treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers urinary tract infection (UTI) treatment market segmentation by type (uncomplicated UTI and complicated UTI) and geography (North America, Europe, Asia, and ROW). The urinary tract infection (UTI) treatment market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd. among others.
Download the Free Report Sample to Unlock the Urinary Tract Infection (UTI) Treatment Market Size for the Forecast Period and Other Important Statistics
The relation of UTI with several other factors leading to a rising incidence rate of UTI is notably driving the urinary tract infection (UTI) treatment market growth, although factors such as the development of antibacterial resistance may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the urinary tract infection (UTI) treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Urinary Tract Infection (UTI) Treatment Market Driver
One of the key factors driving growth in the urinary tract infection treatment market is the rising incidence rate of UTIs. Interconnection of UTIs with other healthcare conditions and changing lifestyle habits have led to the rising incidence of the disease. This, in turn, is expected to raise the demand for treatment facilities for UTIs. The disease is more common in women as compared with men. Around 50% of the women globally have a chance of developing UTIs at least once in their lifetime. This accounts for a large population and demands huge attention. Apart from gender, many other factors, such as obesity and diabetes, contribute to the rising incidence of UTIs.
Key Urinary Tract Infection (UTI) Treatment Market Trend
Rising R&D for effective treatment against superbugs/MDR microorganisms is a major trend influencing the urinary tract infection (UTI) treatment market growth. The development of MDR microorganisms is a huge challenge for the infectious disease industry, with hospital-acquired UTI being one of the major cases among them. Infections due to new species of microorganisms, which are also called superbugs, are resistant to most of the available treatments. These MDR microorganisms have a mortality rate of 25%-60%. This is a huge concern for healthcare providers across the globe. For instance, researchers at Queen's University Belfast, Ireland, have been studying the factors responsible for superbugs being resistant to the first line of treatment. This, in turn, has opened the opportunities to understand and develop a potential treatment to fight against killer infectious diseases. Countries all over the world are witnessing this problem, and therefore, a huge investment is expected in the development of their treatment. The EU, the Government of Canada, and a few developed countries have also taken various steps in developing innovative treatments against antimicrobial-resistant microorganisms.
Key Urinary Tract Infection (UTI) Treatment Market Challenge
The development of antibacterial resistance will be a major challenge for the urinary tract infection treatment market. UTI is primarily a bacterial infection. The development of antibacterial resistance organisms is a huge challenge for the global UTI treatment market. MDR microorganisms make UTIs more severe. MDR microorganisms are the species of organisms that exhibit resistance to several antimicrobial drugs. MDR bacteria are considered the most threatening group among all these organisms as they have shown a significant impact on public health. The MDR microorganisms, such as MDR E. coli, have been found to be a major infecting organism, especially in healthcare settings, and are a major point of concern for healthcare providers.
This urinary tract infection (UTI) treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the global UTI treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the urinary tract infection (UTI) treatment market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the urinary tract infection (UTI) treatment market encompasses successful business strategies deployed by the key vendors. The urinary tract infection (UTI) treatment market is fragmented and the vendors are deploying organic and inorganic strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The urinary tract infection (UTI) treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the urinary tract infection (UTI) treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of pharmaceuticals includes the following core components:
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Disease type
6 Customer landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.